Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia

Internal Medicine Journal

Volumn 40, Issue 2, 2010, Pages 139-149

  Connell, W ^a   Andrews, J M ^b,c   Brown, S ^a   Sparrow, M ^d  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d Alfred and Box Hill Hospitals ^*  (Australia)

Author keywords

Adalimumab; Anti TNF therapy; Crohn's disease; Guidelines; Infliximab; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANTIVIRUS AGENT; AZATHIOPRINE; BCG VACCINE; CORTICOSTEROID; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INFLUENZA VACCINE; ISONIAZID; MEASLES MUMPS RUBELLA VACCINE; METHOTREXATE; ORAL POLIOMYELITIS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ANTIBODY; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANAPHYLAXIS; ANUS FISTULA; ARTHRALGIA; AUSTRALIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BCG VACCINATION; BRONCHOSPASM; CANCER RISK; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ECZEMA; ENTERITIS; FATIGUE; FLUSHING; GUILLAIN BARRE SYNDROME; HEART PALPITATION; HEPATITIS; HEPATITIS B; HERPES ZOSTER; HUMAN; HYPOTENSION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFLUENZA; INFLUENZA VIRUS A H1N1; INTESTINE ANASTOMOSIS; INTESTINE RESECTION; LIVER FUNCTION TEST; LIVER INJURY; LUPUS LIKE SYNDROME; LYMPHOMA; MEASLES; MONOTHERAPY; MULTIPLE SCLEROSIS; MUMPS; MYALGIA; MYCOSIS; NAUSEA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; POLIOMYELITIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROCTOCOLECTOMY; PSORIATIC PUSTULAR ECZEMA; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; RUBELLA; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; ULCERATIVE COLITIS; URTICARIA; VIRUS INFECTION; WART VIRUS; YELLOW FEVER;

ADVISORY COMMITTEES; ANTIBODIES, MONOCLONAL; AUSTRALIA; HUMANS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77749252893     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02122.x     Document Type: Review

References (53)

1. Panaccione R, Fedorak RN, Aumais G, Bernstein CN, Bitton A, Croitoru K et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol 2004 18 : 503 508.
2. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
3. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Intern Med J 2001 31 : 146 150.
4. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999 117 : 761 769.
5. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002 359 : 1541 1549.
6. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006 130 : 323 333 quiz 591.
7. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007 132 : 52 65.
8. Baert F, Noman M, Vermeire S, Van Assche G, G DH, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003 348 : 601 608. (Pubitemid 36204954)
9. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006 63 : 433 442 quiz 64.
10. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004 350 : 876 885.
11. Schreiber S, Colombel JF, Sandborn WJ, Hommes D, Li J, Kent JD et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: Sub-analysis of CHARM. Gastroenterology 2007 132 (Suppl 2 A147, Abstract 985.
12. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002 8 : 244 250.
13. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008 371 : 660 667.
14. Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009 136 : 441 450 e1; quiz 716.
15. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 2476. (Pubitemid 41770166)
16. Jarnerot G. Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2006 130 : 286 author reply 87.
17. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005 34 : 19 22.
18. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007 357 : 239 250. (Pubitemid 47080388)
19. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008 134 : 1861 1868.
20. Feagan B, McDonald JW, Ponich TP. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD) [late-breaking abstract]. Gastroenterology 2008 134 : 682C.
21. Sandborn WJ, Rutgeerts P, Reinisch W. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy [late breaking abstract]. Am J Gastroenterol 2008 103 : Abstract 29.
22. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 2285.
23. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006 4 : 621 630.
24. Toruner M, Loftus EV Jr., Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 : 929 936.
25. Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008 58 : 947 952.
26. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 345 : 1098 1104.
27. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005 52 : 1766 1772.
28. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004 2 : 309 313.
29. Gupta A, Street AC, Macrae FA. Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease. Med J Aust 2008 188 : 168 170.
30. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008 57 : 549 558.
31. Versluis DJ, Beyer WE, Masurel N, Wenting GJ, Weimar W. Impairment of the immune response to influenza vaccination in renal transplant recipients by cyclosporine, but not azathioprine. Transplantation 1986 42 : 376 379.
32. Torre-Cisneros J, Del Castillo M, Caston JJ, Castro MC, Perez V, Collantes E. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 2005 44 : 1132 1135.
33. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004 53 : 1363 1365.
34. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006 21 : 1366 1371.
35. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001 13 : 191 192.
36. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003 62 : 1078 1082.
37. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005 54 : 1121 1125.
38. Siegel C, S M, S P, R L, Sands BE. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's Disease: a meta-analysis. Gastroenterology 2008 134 A144 : Abstract 970.
39. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007 44 : 265 267.
40. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008 57 : 1639 1641.
41. Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006 55 : 228 233.
42. Lees CW, Ironside J, Wallace WA, Satsangi J. Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med 2008 359 : 320 321.
43. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003 98 : 1315 1324.
44. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007 86 : 242 251.
45. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003 125 : 32 9.
46. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006 65 : 889 894.
47. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 2006 54 : 1429 1434.
48. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Rowert J et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. Br J Dermatol 2007 156 : 486 491.
49. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009 36 : 635 641.
50. Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol 2009 36 : 465 466.
51. O'Donnell S, O'Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther 2008 27 : 885 894.
52. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006 4 : 1255 1258.
53. Kane S, Ford J, Cohen R, Wagner C. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's Disease before and after delivery. J Clin Gastroenterol 2009 43 : 613 616.